Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $351.00 by Analysts at Leerink Partners

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target decreased by equities researchers at Leerink Partners from $370.00 to $351.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Partners’ price target indicates a potential downside of 10.35% from the company’s current price.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. lowered their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Evercore ISI upped their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Twenty-three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $477.44.

Alnylam Pharmaceuticals Trading Down 1.5%

ALNY traded down $6.01 on Monday, hitting $391.54. The company had a trading volume of 941,109 shares, compared to its average volume of 1,008,331. The company’s fifty day moving average price is $452.35 and its 200 day moving average price is $408.12. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The firm has a market cap of $51.73 billion, a P/E ratio of 1,631.40 and a beta of 0.30.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,405 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $635,130.25. Following the transaction, the executive vice president directly owned 27,438 shares in the company, valued at approximately $12,403,347.90. This trade represents a 4.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 10,000 shares of the company’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,517,119.43. This trade represents a 13.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 60,328 shares of company stock worth $27,288,993. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after purchasing an additional 2,483,697 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.